1/114
Looks like no tags are added yet.
Transfusion Reaction Definition
Any transfusion-related adverse event occurring during or after transfusion of whole blood, components, or plasma products.
Major Categories of Transfusion Reactions
Acute vs. delayed, immune vs. non-immune, and infectious vs. non-infectious reactions.
Initial Step in Transfusion Reaction Recognition
Involves the patient, the transfusionist, and the physician responsible for the patient at the time of transfusion.
Intermediate and Final Steps in Transfusion Reaction Evaluation
Involves the Transfusion Service technical staff and the Transfusion Service physician.
Immediate First Step When Investigating a Potential Reaction
Stop the transfusion.
Fever Criterion for a Transfusion Reaction
Fever of 39°C or higher, or a rise of 2°C or more.
Hypoxemia Criterion for a Transfusion Reaction
Oxygen saturation below 90%.
Tachycardia Criteria for a Transfusion Reaction
Heart rate above 120/min or a rise of greater than 40/min.
Tachypnea Criterion for a Transfusion Reaction
Respiratory rate greater than 28/min.
Blood Pressure Criteria for a Transfusion Reaction
Hypertension (rise in BP >30 mmHg) or Hypotension (drop in BP >30 mmHg).
Pain Symptoms in Transfusion Reactions
Abdominal, back, chest, infusion site pain, and headache.
Renal Signs of Transfusion Reactions
Hematuria, hemoglobinuria, and oliguria or anuria.
Cutaneous Manifestations of Transfusion Reactions
Urticaria, pruritus, and rash.
AABB Clerical Check Requirements
Check the component bag, label, paperwork, and pretransfusion patient specimen.
AABB Laboratory Testing Requirements
Repeat ABO testing on post-transfusion sample and perform a direct antiglobulin test (DAT).
AABB Visual Specimen Check
Visual check of pre- and post-transfusion specimens for hemolysis.
AABB Component Quarantine Requirement
Quarantine additional components prepared from the same donor collection.
AABB Reporting Requirement
Report findings to the transfusion service supervisor or medical director.
Key Respiratory Transfusion Reactions to Compare
Transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and transfusion-associated dyspnea.
Transfusion-Transmitted Bacterial Infection Comparison
Compare clinical manifestations and microbiology between contaminated RBC versus platelet products.
AHTR Immune Mechanism
Recipient IgM or IgG antibodies recognize donor red cell antigens, forming immune complexes and activating complement.
AHTR Laboratory Evaluation Findings
Positive DAT, decreased haptoglobin, elevated bilirubin and LDH, hemoglobinemia, and hemoglobinuria.
DHTR Timeline and Cause
Presents 24 hours to 28 days post-transfusion due to an amnestic or primary immune response.
TRALI Pathogenesis Pathways
Immune TRALI via leukocyte antibodies and non-immune TRALI via a two-hit patient predisposition model.
TRALI Radiographic Finding
Classic bilateral 'white-out' appearance of non-cardiogenic pulmonary edema.
TACO Pathophysiology
Cardiovascular system workload is exceeded, manifesting as congestive heart failure and fluid overload.
TACO At-Risk Populations
Pediatric patients, patients with severe anemia, and CHF patients.
Hypotensive Transfusion Reaction Cause
Potentially caused by increased bradykinin levels in stored blood products.
FNHTR Primary Prevention
Leukoreduction of blood products.
Allergic Transfusion Reaction Prophylaxis
Antihistamines or corticosteroids given prior to or during transfusion for patients with a reaction history.
TA-GVHD Mechanism
Transfused viable donor T-lymphocytes mount an immunologic attack against recipient host tissues.
TA-GVHD Prevention Method
Gamma irradiation of blood units.
Post-Transfusion Purpura (PTP) Treatment
Intravenous immunoglobulin (IVIg) or plasma exchange for unresponsive cases.
Iron Overload Management
Chelation therapy to address multi-organ damage from excessive iron accumulation.
Common Platelet TTBI Pathogens
Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus lugdunensis.
Common RBC TTBI Pathogens
Enterobacter cloacae, E. coli, Klebsiella species, Pseudomonas aeruginosa, and Serratia marcescens.
Silent Transfusion-Related Adverse Events
Incidents like sample collection errors, overdosing/underdosing, and red cell or platelet alloimmunization.
Transfusion Reactions Presenting With Fever
AHTR, FNHTR, TAS, TRALI, DHTR, and TA-GVHD.
Transfusion Reactions Presenting Without Fever
DSHTR, PTP, Iron Overload, Allergic, Hypotensive, TAD, TACO, and Acute Pain.
Definition of HDFN
Destruction of fetal or neonatal red blood cells by antibodies produced by the pregnant individual.
Primary Cause of HDFN
About 95% of cases are caused by maternal antibodies directed against the Rh antigen D (anti-D).
IgG Subclasses in HDFN
IgG1 and IgG3 are the most efficient subclasses in causing RBC hemolysis and crossing the placenta.
Rh HDFN Firstborn Phenomenon
An Rh-positive firstborn infant of an Rh-negative parent is usually unaffected because the parent has not yet been immunized.
Fetomaternal Hemorrhage Timing
Transplacental hemorrhage occurs in up to 7% of pregnancies during gestation and over 50% at delivery.
Clinically Significant Non-Rh Antibody
Anti-Kell is considered the most clinically significant non-Rh antibody in its ability to cause HDFN due to its presence on immature erythroid cells.
Erythroblastosis Fetalis
Condition where immature fetal RBCs (erythroblasts) are released into circulation due to accelerated bone marrow production responding to hemolysis.
Hydrops Fetalis
Severe anemia and hypoproteinemia leading to high-output cardiac failure with generalized edema, effusions, and ascites.
Bilirubin Processing in Fetus vs Newborn
Indirect bilirubin from fetal RBC destruction is conjugated in the maternal liver; after birth, the immature newborn liver cannot adequately process unconjugated bilirubin.
ABO HDFN Characteristics
Nearly always limited to A or B infants of group O individuals, can occur in the first pregnancy, and is generally milder than Rh HDFN.
Protective Effect of ABO Incompatibility
Major ABO incompatibility between mother and fetus can protect against Rh immunization by destroying fetal cells before the D antigen is recognized.
Prenatal Antibody Screening Timing
Recommended obstetric practice is to perform type and antibody screen at the first prenatal visit, preferably in the first trimester.
Antibody Titration Significance
A difference of greater than 2 dilutions or a titer score change of 10 or more is considered clinically significant.
Paternal Genotyping Purpose
If the pregnant individual has anti-D and the father is D-positive, zygosity testing helps determine if the father is homozygous or heterozygous for the D antigen.
Fetal DNA Testing Window
Amniocentesis or chorionic villous sampling can be performed as early as 10 to 12 weeks' gestation to determine fetal blood group genes.
Rh Immune Globulin (RhIg) Impact
The incidence of HDFN caused by anti-D has steadily decreased since 1968 due to the introduction of RhIg.
Antibody Titer Threshold for MCA-PSV
A titer reproducibly at 32 or above indicates a need for Color Doppler MCA-PSV studies after 16 weeks' gestation.
MCA-PSV Monitoring for Titers Below 32
Repeated at 4-week intervals from 16-20 weeks, then every 2 to 4 weeks in the third trimester.
Amniocentesis in HDFN Management
Uncommonly used because MCA-PSV is noninvasive; measures bilirubin pigment via Delta OD 450 nm.
Intrauterine Transfusion Triggers
Fetal Hb less than 10 g/dL, high Delta OD 450 nm, MCA-PSV indicating anemia, or fetal hydrops on ultrasound.
Intrauterine Transfusion Procedure
Performed by accessing the fetal umbilical vein and injecting donor RBCs directly into the vein.
Cord Blood Testing Challenges for Newborns
ABO antigens and isoagglutinins are not fully developed, causing weak reactions and missing reverse testing.
Blocked Rh Phenomenon in Cord Blood
Can cause false-negative Rh typing and positive Direct Antiglobulin Tests (DAT) due to heavy antibody coating.
Phototherapy Wavelength and Action
Uses 460 to 490 nm light to convert unconjugated bilirubin into less lipophilic, less toxic isomers.
Primary Purpose of Exchange Transfusion
Primarily used to remove high levels of unconjugated bilirubin, maternal antibodies, and sensitized RBCs.
Newborn Transfusion Thresholds
Hemoglobin levels below 10 g/dL may require transfusion, while levels below 7 g/dL indicate severe anemia and hypoxia.
Blood Selection Criteria for HDFN Transfusions
Group O RBCs, antigen-negative for maternal antibodies, CMV-negative, irradiated, and Hgb S negative.
Intravenous Immune Globulin (IVIG) Mechanism
Competes with maternal antibodies for Fc receptors on macrophages in the infant's spleen, reducing hemolysis.
Mechanism of RhIG Prevention
RhIG binds to fetal Rh-positive cells in maternal circulation, leading to their removal by macrophages in the maternal spleen.
Antenatal RhIg Administration Timing
Given early in the third trimester (around 28 weeks) due to the risk of immunization during pregnancy.
Postpartum RhIg Timing
Rh-negative nonimmunized patients should receive RhIG within 72 hours after delivery of an Rh-positive infant.
Fetal-Maternal Hemorrhage Rosette Screen Principle
Maternal RBCs are incubated with anti-D, washed, and mixed with D-positive indicator cells that form rosettes around coated cells.
Kleihauer-Betke Test Purpose
Recommended following a positive screen to quantify the amount of fetal bleed and determine the exact RhIG dosage.
RhIG Regular-Dose Vial Capacity
Contains sufficient anti-D to protect against 15 mL of packed RBCs or 30 mL of whole blood.
Kleihauer-Betke Dosage Calculation Formula
Number of Rh vials equals the Volume of Fetal Bleed divided by 30 mL.
Management of Weak D Individuals
Treated as Rh-negative and given RhIG if genetic testing is unavailable, due to the risk of mosaic D producing anti-D.
Autoantibody Definition
Antibodies directed against an individual's own red blood cells.
AIHA Categories
Alloimmune, Autoimmune hemolytic anemia (AIHA), and Drug-induced immune hemolytic anemia (DIIHA).
Immune Regulatory Failure in Autoantibodies
Loss of suppressor T-cell function preventing excessive B-cell proliferation and antibody overproduction.
Compensated vs Uncompensated AIHA
In compensated anemia, RBC production nearly equals destruction; in uncompensated anemia, destruction exceeds production.
Diagnostic Tests for AIHA
Direct antiglobulin test (DAT) and characterization of autoantibody in serum or eluate using standard identification.
AIHA Thermal Reactivity Distribution
Warm reactive accounts for ~70%, cold reactive for ~18%, and drug-induced for ~12% of reported cases.
Benign Cold Agglutinins
Low titer (
Cold Agglutinins Interference in Testing
Can cause false-positive ABO typing, positive DAT with polyspecific AHG, and interference at the AHG phase.
Anti-I vs Anti-i Specificity
Anti-I reacts strongly with adult cells and weakly with cord cells; anti-i reacts strongly with cord cells and weakly with adult cells.
Anti-H and Anti-IH in Cold Agglutinins
Found in group A1 and A1B sera; react best with group O and A2 cells which have the largest amounts of H antigen.
Pathologic Cold Autoagglutinins
Characterized by reactivity >30°C, typical titer >1000, strong albumin enhancement, and stronger DAT reactions due to C3.
Cold Hemagglutinin Disease (CHD) Association
Chronic or acute cold AIHA often associated with Mycoplasma pneumoniae pneumonia or Infectious Mononucleosis.
Cold Hemagglutinin Disease Immunoglobulin Type
Usually an IgM immunoglobulin that efficiently activates complement.
CHD Clinical Picture and Symptoms
Acrocyanosis, numbness in extremities, and hemoglobinuria exacerbated by cold exposure.
Paroxysmal Cold Hemoglobinuria (PCH)
Least common AIHA, often seen in children after viral illnesses, characterized by episodic hemoglobinuria upon cold exposure.
Donath-Landsteiner Antibody
A biphasic autohemolysin with anti-P specificity that binds at low temperatures and causes complement-mediated intravascular lysis at 37°C.
Donath-Landsteiner Test Procedure
Subjects serum/plasma to 4°C followed by 37°C incubations to confirm the presence of the biphasic hemolysin via hemolysis.
Drug-Induced Immune Hemolytic Anemia (DIIHA) Definition
Immune destruction of RBCs, white blood cells, or platelets caused by therapeutic drugs.
DIIHA Blood Bank Presentation
Typically identified by diagnostic testing requests for suspected hemolytic anemia or unexpected positive DAT results.
Unifying Hypothesis Mechanisms in DIIHA
Includes drug binding to RBC membrane, drug-antibody complexing (innocent bystander), and drug-induced autoantibody formation.
Drug-Adsorption (Hapten) Mechanism
Drugs bind firmly to RBC membrane proteins, with penicillin being the drug most commonly associated.
Penicillin-Induced DIIHA Characteristics
Penicillin antibodies causing positive DAT are most often IgG; patient serum is non-reactive with reagent RBCs.
Drugs Causing Positive DAT via Drug-Adsorption
Penicillin, cephalosporins, and cefotetan.
Drug-Dependent or Immune Complex Mechanism
Drug interacts non-covalently with membrane proteins to form a 'neoantigen' that binds drug antibodies.
Clinical Features of Immune Complex DIIHA
Frequently presents with acute intravascular hemolysis and renal failure, requiring immediate drug cessation.